Mast Therapeutics, Inc.(MSTX) was a big mover last session, as the company saw its shares rise above 7% on the day. The upside came on solid volume with far more shares changing hands than in a normal session. This reverses the recent downtrend for the company since Sep 23, as the stock is now down almost 10%.
In the last 30 days, the company has seen no estimate revision and the Zacks Consensus Estimate also remained unchanged The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Mast Therapeutics holds a Zacks Rank #2 (Buy), while its Earnings ESP is 0.00%.
Another favorably-placed bio-medical/gene stock is Emergent BioSolutions, Inc. (EBS) , which sports a Zacks Rank #1 (Strong Buy).